[ad_1]
TOKYO and TEL AVIV, Israel, September 30, 2021 / PRNewswire / – CytoReason, an AI company that develops computer models of diseases for clinical drug discovery and development, and International Pharmaceutical Summit (SPI), a Japanese company providing services and products to the pharmaceutical industry (a 100% subsidiary of Sumitomo Corporation), today announced that CytoReason has entered the Japanese market with its technology being used by one from from Japan large pharmaceutical companies.
logo
CytoReason’s AI platform will use its disease model, along with clinical data from the Japanese pharmaceutical company, to help it better understand how its drug behaves at the molecular level, compared to similar drugs on the body. Marlet.
This is the first ever collaboration announced between an Israeli company and a Japanese pharmaceutical company to bring AI to clinical drug development. The collaboration will explore the relationship between disease mechanisms and the drug’s MoA in order to increase the value of the drug in immunology. It is particularly impactful because Japan has the third largest pharmaceutical market in the world.
CytoReason helps pharmaceutical and biotechnology companies accelerate drug discovery and development through the use of its cell-centric computer models and proprietary data. The company’s technology enables scientists to gather critical information about the body’s immune function, which ultimately speeds up the scientific process and brings life-saving drugs to market faster and at lower cost. R&D using AI technology is becoming essential in the pharmaceutical field and the industry has taken a keen interest in CytoReason’s technology. The Sumitomo Corporation group is facilitating digital transformation in various industries, and SPI intends to further support data-driven drug discovery and clinical development through CytoReason’s proprietary AI / machine learning platform.
“We are delighted to enter the Japanese market with such an important player in the country’s pharmaceutical industry,” said David Harel, CEO and co-founder of CytoReason. “This collaboration represents a significant step forward for our company and for the global pharmaceutical industry.”
“We are very happy that CytoReason has launched a project in the Japanese market,” said Katsuya Okuyama, President and CEO of SPI. “We will continue to contribute to the healthcare industry through the collaboration with CytoReason. “
About CytoReason
CytoReason’s computer model of the human body simulates human disease at the cellular level, minimizes the need for animal testing, and makes human trials more focused and precise. With CytoReason’s proprietary database and AI-driven platform, pharmaceutical and biotech companies are making data-driven decisions in a fraction of the time and cost. To date, six of the world’s ten largest pharmaceutical companies use CytoReason technology to get the right medicine, to the right patient, at the right price. For more information visit www.cytoreason.com.
About SPI
SPI is a provider of high quality integrated products and services to the pharmaceutical industry, ranging from research equipment and bioresources for drug discovery, pharmaceutical licensing and support to research alliances, to manufacturing APIs, intermediates for pharmaceuticals, generics and biologics. SPI plays a central role in the medical sciences industry as a group company of Sumitomo Corporation, with one of the world’s leading trading companies, 113 sites in 66 countries and 22 sites in Japan, with a diverse range of products and services. For more information visit http://www.summitpharma.co.jp.
Media contact
Yael Hart
GK for CytoReason
[email protected]
SOURCE CytoReason
[ad_2]
